NA Selank Amidate

N. A. Selanki ʻAmitā

N. A. Selanki ʻAmitā

Tali vave

Professional NA Selank Amidate peptide provided by trusted manufacturer and factory. Offer wholesale N-Acetyl Selank Amidate peptides for biomedical laboratory neuroscience and neuroprotective research projects.

NA Selank Amidate exhibits improved molecular stability and in vivo pharmacokinetic profile through a double-modification strategy of N-terminal acetylation and C-terminal amidation based on the original structure of Selank.

 

SKU: 198884 Fakakalakalasi:
Vahevahe ho'o 'ofa

NA Selank Amidate exhibits improved molecular stability and in vivo pharmacokinetic profile through a double-modification strategy of N-terminal ʻasetila and C-terminal amidation based on the original structure of Selanki.

This results in an increased half-life, fakalahi toto mo e ʻuto penetration efficiency, and prolonged bioactivity in both molecular and animal models.

Pea mo e, NA Selank Amidate exhibits potent immunomodulation and anti-stress activity.

Fakahokohoko

ac-thr-lys-poupou-'aki-po-gly-poupou-nh2.

Fika CAS

/

Fomula Molekula

C35H60N12O9

Mamafa Molekula

792.94

Research Of NA Selank Amidate

1.Retained and Enhanced Efficacy

Efficacy-wise,NA Selank Amidate retains all of the characteristics of Selank, fakatonutonu gamma-aminobutyric acid (GABA) neurotransmission in the brain while also modulating the topaminelisi mo e selotoni systems to deliver outstanding hohaʻa mo e antidepressant effects.

It also shows better efficacy than Selank in enhancing cognitive and neuroprotective functions, producing pronounced positive effects on learning, memory, and attention.

2.Anxiolytic and Mood-Stabilizing Effects

In a concentration-dependent and subtype-selective manner, N. A. Selanki ʻAmitā allosterically modulates ko e GABA-A receptor by potentiating the binding efficacy of GABA to its receptor or enhancing chloride ion channel opening efficiency.

This significantly increases the inhibitory tone in key brain circuits, producing marked anxiolytic effects.

Tanaki atu, the side effects of this anxiolytic action are significantly milder than those of conventional anxiolytic drugs, making NA Selank Amidate a more attractive mood-stabilizing compound.

3.Cognitive Enhancement and Neuroprotection

NA Selank Amidate directly activates BDNF gene transcription by inducing fosifolaila of the promoter-located CREB transcription factor and acetylation of histone H3, increasing BDNF mRNA levels 3.2-fold in hippocampal dentate gyrus granule cells and prefrontal cortical pyramidal neurons and protein secretion 2.8-fold within 24 ngaahi houa.

This activates the TrkB receptor signaling pathway downstream, inducing the Ras-MAPK and PI3K-Akt cascade to increase tuʻasino dendritic density by 39%, upregulate synaptophysin expression by 45%, and restore LTP amplitude to baseline.

This successfully prevents stress-induced hippocampal neuronal injury and cognitive decline, demonstrating distinct neuroprotective properties.

4.Immunomodulatory and Anti-Stress Effects

NA Selank Amidate is a competitive inhibitor of enkephalin-degrading enzyme, protecting endogenous peptides opioid mei hydrolysis and thereby elevating their levels, while it inhibits LPS (lipopolysaccharide)-induced expression of pro-inflammatory saitokaini ʻo kau ai IL-6. mo e TNF-α by 40–60% in astrocytes.

NA Selank Amidate also represses NF-κB nuclear translocation by interfering with the recruitment of MyD88 adaptor protein, providing protective regulation in the neuroinflammatory microenvironment.

COA

HPLC

MS

(1) ʻOku mau fie, C. R.; Hinehina, C. M. Ngaahi me'a fakanonga-fakamohe 'oku ne uesia 'a e ngaahi tali 'o e 'esiti Gamma-Aminobutyric: Tokangataha ki he Flunitrasepam, ʻEsiti Kama-Haitolokisipeutiliki, Fenipati, mo Selanki .. J Clin Faito'o 2021, 61 Tuku 2, S114-S128. DOI: 10.1002/jcph.1922 From NLM M

(2) Me'a masiva, HA.; Kolomini, T.; ʻAniteleva, L.; Ponitāleniko, E.; Miasoetovi, N.; Slominisiki, P.; Satilina, M. Peptide Selank fakalahi 'a e ola 'o e Diazepam 'i hono fakasi'isi'i 'o e hoha'a 'i he ngaahi tu'unga 'o e mafasia ma'ama'a 'oku 'ikai lava ke tomu'a tala 'i he fanga ki'i ikale .. Neulo ʻo e ʻUlungaangá 2017, 2017, 50910

(3) Pine, L. G.; Natolova, HA. V.; ʻAnitipova, T. HA.; Kulukolovi, S. V.; Kutilini, V. Ko S.; Tunevi, HA. D. Selanki, Pepitaiti 'analaiso 'o e Tuftsin ., Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex

(4) Pine, L. G.; Natolova, HA. V.; Seletenini, S. B. 'Oku ta'ofi 'e he Selank 'a e Hyperlocomotion 'oku fakatupu 'e he 'Etanolo mo e fakahaa'i 'o e 'ulungaanga 'o e ongo'i 'i he DBA/2 Mice .. Pulu Exp Paiolosia Med 2016, 162 (1), 56-59. DOI: 10.1007/s10517-016-3544-6 From NLM Medline.

(5) Totongi, N. V.; Sokolov, O.; Kapaeva, M. V.; Kalivenikovi, Ko au. HA.; ʻAniteleva, L. HA.; Miasoetovi, N. F.; Sosulia, HA. HA. ['Oku ta'ofi 'e he Semax mo e selank 'a e ngaahi 'enisaimi 'oku faka'auha 'e he enkephalin mei he toto 'o e tangata .]]. Bioorg Khim 2001, 27 (3), 180-183. DOI: 10.1023/ha:10113730028

(6) Oku 'ikai ke u 'ilo'i, G. G.; Telesova, E. Ko S.; Pokalevi, V. K.; Koselevi, V. V.; Siuniakovi, T. S. P.3.036 Ko e Selank fakahohaʻa foʻou: Ngaahi ola 'o e ngaahi 'ahi'ahi fakakiliniki 'o e Phase II. Fakafaitoʻo fakaʻatamai ʻIulope 2005, 15, S159-S160. DOI: 10.1016/s0924-977x(05)80332-3.

(7) Slominisiki, P. HA.; Satilina, M. KO AU.; Kolomini, T. HA.; Sitālovisikaya, HA. V.; Filatova, E. V.; ʻAniteleva, L. HA.; ʻIlaliosikini, S. N.; Miasoetovi, N. F. 'Oku uesia 'e he peptides semax mo e selank 'a e 'ulungaanga 'o e fanga ki'i ikale mo e 6-OHDA fakatupu 'e he PD-hange ko e parkinsonism .. Dokl Biol Sc

(8) Soletiniskaja, T. N.; Solokovi, M. V.; Miasoetovi, N. F. Ko e ngaahi ola malu'i 'o e 'atamai 'o e Semax mo e Selank 'i he primates 'i he ngaahi fa'ahinga kehekehe 'o e neurosis .. Tohinoa Fakavaha'apule'anga 'o e Saikofisiolosia 2008, 69 (3). DOI: 10.1016/2008.05.356.

Fakahokohoko:

ac-thr-lys-poupou-'aki-po-gly-poupou-nh2.

CAS:

/

M.W:

792.94 g/mol

Api Kumi Whatsapp Ngaahi Sevesi Koloa